The MHRA have extended the swine flu adverse drug reaction (ADR) portal to include swine flu vaccines and seasonal vaccines.
In July 2009 the MHRA launched a special swine flu ADR portal for reporting suspected adverse drug reaction to oseltamivir (Tamiflu) and zanamivir (Relenza).
The MHRA now have extended use of this portal to include suspected ADRs to new swine flu vaccines and seasonal vaccines.
Reports should include;
- the patient’s age;
- a description of the suspected adverse reaction and outcome;
- any underlying risk factors.